Update on targeting EGFR in advanced non-small-cell lung cancer
- VernacularTitle:表皮生长因子受体通路阻断治疗晚期非小细胞肺癌
- Author:
Xinghao AI
;
Shun LU
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Receptor,epidermal growth factor;
Targeted therapy;
Signal transduction
- From:
Cancer Research and Clinic
2008;20(5):289-294
- CountryChina
- Language:Chinese
-
Abstract:
The results of chemotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC)had reached a plateau.Targeted therapy is the key to improving efficacy.In the last 5 years the epidermal growth factor receptor(EGFR)has emerged as one of the most important targets for drug development in oncology.Small molecules that inhibit the tyrosine kinase(TK)domain of EGFR have become new critical weapons in the treatment of NSCLC.Monoclonal antibodies targeting the external domain of EGFR have been shown to have clinical benefit when combined with chemotherapy.Recent data suggest that multitargeted inhibitors might have greater activity owing to their ability to simultaneously block key signaling pathways.Preliminary results of such agents in clinical trials shows that they have a well-tolerated toxicity profile,and might have a promising value in the treatment of advanced non-small-cell lung cancer.
